Back to Health

Who Should Avoid Atazanavir?

Who Should Avoid Atazanavir?
Bareback Guide 5 May 2026

Atazanavir works well for the people it suits. The situations where it does not are mostly about what else you take rather than about the drug itself.

Who is excluded by acid-reducing medication?

Anyone who needs a proton pump inhibitor long term and cannot stop it. Atazanavir absorption falls substantially, which risks treatment failure. For someone with reflux disease requiring continuous treatment, a different antiretroviral is usually the sensible answer.

Who is excluded by other interactions?

Anyone taking rifampicin for tuberculosis, St John's wort, or one of the medicines contraindicated with boosters. The list is long enough that it is worth checking rather than assuming, and the checking takes minutes.

What about liver impairment?

Atazanavir is cleared by the liver. A reduced dose may be used in moderate impairment and it is not recommended in severe impairment. Anyone with significant liver disease, including advanced hepatitis B or C, needs this considered.

What about heart conduction problems?

Atazanavir prolongs the PR interval, so caution applies for anyone with existing conduction abnormalities or taking other medicines with the same effect. This is usually a matter for monitoring rather than exclusion.

What about the jaundice?

Not a medical contraindication and a perfectly good reason to choose something else. Visible yellowing that prompts questions from colleagues or family amounts to an unwanted disclosure for some people, and that is sufficient grounds to switch.

What about a history of kidney stones?

Worth raising, since atazanavir is associated with an increased incidence. Someone who has had stones before may reasonably prefer an alternative.

What about recreational drug use?

Not a prohibition and a genuine safety consideration. Boosters raise levels of several substances to dangerous degrees, and switching to an unboosted regimen is a legitimate clinical reason that clinics take seriously.

What about pregnancy?

Used in pregnancy with an established record, and dosing may need adjusting in the later stages because levels fall. The bilirubin effect can appear in the newborn and is monitored. Raise a pregnancy or a plan for one early.

What about resistance?

Existing protease inhibitor resistance may reduce its activity, and resistance testing determines whether it remains useful. Darunavir generally retains activity against a wider range of resistance patterns.

What are the alternatives?

Integrase inhibitors such as dolutegravir and bictegravir, which are first-line, unboosted, better tolerated and free of the acid and interaction problems. Darunavir where a protease inhibitor is specifically wanted. Doravirine among the newer non-nucleosides.

Can you switch away easily?

Yes, and it is common. Switching from a boosted protease inhibitor to an unboosted integrase inhibitor is routine for people who are suppressed, and it usually simplifies the interaction picture considerably.

Who decides?

You do, with a clinician. Suitability is a clinical judgement and the choice between suitable options is yours, including on grounds like appearance, tablet burden and how a regimen fits your life.

What should you tell your clinic?

Everything you take including over-the-counter products, particularly anything for indigestion, any inhaler, and any recreational drug use. The interaction picture on a boosted regimen depends entirely on having a complete list.

What if it is the only option available?

Rarely the case. HIV medicine has enough options that almost every situation has an alternative, and where choices genuinely are limited a specialist will construct something around your resistance profile.

Is a second opinion reasonable?

Entirely. If you have been told atazanavir is your only option, or that you cannot change, asking to discuss it again or to see someone else is a normal part of care rather than a complaint about anyone.

What happens if you have to change?

Switching is routine and suppression is maintained provided the new regimen is fully active. Coming off atazanavir is not a setback and it does not narrow your options later, since most changes are reversible.

What should you bring to the conversation?

What is actually bothering you, in concrete terms, and what you would want instead if it were possible. That produces a more useful discussion than a general sense that something is not right.